摘要
目的探讨比索洛尔联合阿托伐他汀治疗顽固性心绞痛患者的临床疗效,及其对血清炎症因子的影响。方法选取2018年11月—2020年2月在周口市第一人民医院收治的84例顽固性心绞痛患者,采用随机数字表法分为研究组(n=42)和对照组(n=42)。在两组患者均给予常规对症治疗的基础上,对照组采用阿托伐他汀治疗,研究组采用比索洛尔联合阿托伐他汀治疗。比较两组患者治疗前后心绞痛疗效、心电图疗效、炎症因子水平及不良反应发生情况。结果研究组心绞痛疗效和心电图疗效均明显优于对照组(Z=2.083、2.118,P<0.05);与治疗前相比,两组患者治疗后超敏C-反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)及干扰素(IFN-γ)水平较治疗前均明显降低(P<0.05),且研究组较对照组明显降低(P<0.05);研究组与对照组不良反应发生率分别为11.90%、7.14%,两组比较无显著差异(χ^(2)=0.553,P=0.457)。结论比索洛尔联合阿托伐他汀应用于顽固性心绞痛患者疗效显著,可减轻患者临床症状,减轻机体炎症反应。
Objective To investigate the clinical efficacy of the treatment of bisoprolol combined with atorvastatin in patients with intractable angina pectoris,and effect on serum inflammatory factors.Methods A total of 84 patients with intractable angina pectoris in our hospital from Nov.2018 to Feb.2020 were selected and divided into the study group(n=42)and the control group(n=42)by using the random number table method.With the basic conventional symptomatic treatment of the both groups,the control group was treated with atorvastatin,and the study group was treated with bisoprolol combined with atorvastatin.The angina pectoris curative efficacy,electrocardiogram curative efficacy,the level of inflammatory factors and occurrence of adverse reactions of the both groups were compared before and after treatment.Results The angina pectoris curative efficacy and electrocardiogram curative efficacy in the study group were obviously better than those in the control group(Z=2.083,2.118,P<0.05).The levels of high-sensitivity C-reactive protein(hs-CRP),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)and interferon-γ(IFN-γ)of both groups after treatment were obviously decreased in comparison with those before treatment(P<0.05),and the study group was obviously decreased in comparison with those in the control group(P<0.05);The incidence rate of adverse reactions in the study group and the control group were 11.90%and 7.14%respectively,and there was no significant difference were the incidence rate of adverse reactions between both groups(χ^(2)=0.553,P=0.457).Conclusion The efficacy of bisoprolol combined with atorvastatin in patients with intractable angina pectoris is significant,and it can significantly improve the clinical symptoms of patients and reduce the inflammatory response of body.
作者
张梦华
ZHANG Meng-hua(Department of Cardiology,The First People's Hospital of Zhoukou,Zhoukou,Henan 466700,China)
出处
《医药论坛杂志》
2021年第14期36-39,共4页
Journal of Medical Forum
关键词
比索洛尔
阿托伐他汀
顽固性心绞痛
炎症因子
临床疗效
Bisoprolol
Atorvastatin
Intractable angina pectoris
Inflammatory factors
Clinical efficacy
